Table 2 The classification of functional MeSNs for cancer therapy
From: Engineering of bioactive metal sulfide nanomaterials for cancer therapy
Therapy strategies | Functional MeSNs | Cargoes | Release patent | Synergistic treatment | Ref. |
|---|---|---|---|---|---|
Photothermal therapy | Chitosan-stabilized CuS NPs | NA | NA | NA | [19] |
RGD and TAT peptides modified mesoporous silica coated CuS NPs | NA | NA | NA | [12] | |
Clearablemanganese-doped CuS nanodots | NA | NA | NA | [144] | |
Ni9S8 NPs | NA | NA | NA | [45] | |
Bi2S3-gold heterojunction nanorods | NA | NA | NA | [51] | |
Nanoceria decorated flower-like MoS2 nanoflakes | NA | NA | NA | [46] | |
Gold/gold Sulfide NPs | NA | NA | NA | [146] | |
ReS2 NPs | NA | NA | NA | [22] | |
BSA and PEG modified RuS1.7 nanoclusters | NA | NA | NA | [98] | |
Cyclic RGD modified Ag2S NPs | NA | NA | NA | [47] | |
Erythrocyte-cancer hybrid membrane camouflaged hollow CuS NPs | DOX | Photothermal sensitive | Chemotherapy | [39] | |
Doxorubicin and chlorin e6 loaded hollow CuS NPs | Dox and Chlorin e6 | Photothermal sensitive | Chemotherapy | [85] | |
Mesoporous SiO2 encapsulated CuS NPs | siRNA and Adriamycin | Photothermal sensitive | Chemotherapy | [90] | |
Hollow mesoporous NiS NPs | DOX | pH sensitive | Chemotherapy | [48] | |
Antibody-functionalized Bi2S3@mesoporous silica core-shell NPs | DOX | pH and temperature sensitive | Chemotherapy | [89] | |
SnS nanosheets | DOX | NA | Chemotherapy | [72] | |
Polyethylene glycol TaS2 nanosheets | DOX | Photothermal and moderate acidic pH sensitive | Chemotherapy | [40] | |
Urchin-like Bi2S3 NPs | DOX | Photothermal sensitive | Chemotherapy | [69] | |
PEG modified iron oxide-hydroxide nanospindles | NA | pH sensitive Fe2+ release | PTT | [16] | |
WS2 nanosheets | Photosensitizer | NA | PDT | [41] | |
Photodynamic therapy | Co9S8 nanodots | NA | NA | PTT | [67] |
Ag2S NPs | NA | NA | NA | [66] | |
Transferrin modified hollow mesoporous CuS NPs | Artesunate | pH sensitive | Chemotherapy | [70] | |
Bi2S3 nanorods | Zinc protoporphyrin | NA | NA | [50] | |
Radiotherapy | Melanin-PEG coated CuS NPs | DOX | pH sensitive | Chemotherapy | [13] |
Bi2S3@BSA | MTX | Proteinase | Chemotherapy | [57] | |
Folic acid conjugated Bi2S3@BSA | Curcumin | Sustained release | Chemotherapy | [56] | |
Platelet membrane camouflaged mesoporous silica-coated Bi2S3 nanorods | NA | NA | PTT | [49] | |
Ultrasmall Bi2S3 NPs | NA | NA | PTT | [31] | |
Gold-gold sulfide nanoshells | NA | NA | NA | [55] | |
Lipoic acid-PEG modified WS2 quantum dots | NA | NA | PTT | [33] | |
Chemodynamic therapy | Layered double hydroxides-CuS nanocomposites | NA | Photothermal active Cu2+ release | PTT and PDT | [30] |
PEG modified iron oxide-hydroxide nanospindles | NA | pH sensitive Fe2+ release | PTT | [16] | |
PVP-modified CuS nanocrystals | NA | Photothermal active Cu2+ release | PTT and PDT | [52] | |
Gas therapy | Ferrous sulfide embedded FeS@BSA nanoclusters | NA | pH sensitive H2S release | CDT | [14] |
MnS NPs | NA | NA | CDT | [64] | |
PVP-modified multifunctional Fe1 − xS NPs | NA | pH sensitive H2S release | PTT and CDT | [140] | |
ZnS NPs-decorated silica fibre mesh | DOX | pH sensitive H2S release | Chemotherapy | [21] | |
Immunotherapy | Maleimide polyethylene glycol modified CuS NPs | Tumor antigens | Photothermal sensitive | PTT | [44] |
Bi2S3 NPs | Ganoderma lucidum polysaccharide | NA | Radiotherapy | [15] |